• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Orexigen Therapeutics, Inc. (OREX)

    -NasdaqGS
    6.33 Up 0.04(0.64%) Dec 19, 4:00PM EST
    |After Hours : 6.40 Up 0.07 (1.11%) Dec 19, 7:46PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Orexigen Therapeutics, Inc.
    3344 North Torrey Pines Court
    Suite 200
    La Jolla, CA 92037
    United States - Map
    Phone: 858-875-8600
    Fax: 858-875-8650
    Website: http://www.orexigen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:50

    Business Summary 

    Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Orexigen Therapeutics, Inc.

    Corporate Governance 
    Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Michael A. Narachi M.S., M.B.A., 55
    Chief Exec. Officer, Pres and Director
    1.15M0.00
    Mr. Joseph P. Hagan , 45
    Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
    592.00K280.00K
    Ms. Heather D. Turner J.D., 41
    Sr. VP, Gen. Counsel and Sec.
    588.00K0.00
    Mr. Mark D. Booth , 54
    Chief Commercial Officer
    467.00K632.00K
    Dr. Preston S. Klassen M.D., M.H.S., 45
    Head of Global Contrave Program and Sr. VP of Product Devel.
    584.00K551.00K
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders